Calmark's distributor in India also signs agreements for the Neo products

Report this content

Calmark Sweden AB announced today that an exclusive distributor agreement has been signed with r2 Diagnostics in India regarding Calmark's test for newborns.

As previously announced, Calmark has entered an exclusive distributor agreement with the company r2 Diagnostics regarding marketing and sales of Calmark's COVID19-LDH test in India. This is now being expanded with the Neo products where the first to be launched is Neo-Bilirubin.

Every year, about 25 million children are born in India. Of these, it is estimated that about 30% need to take at least one blood sample to ensure bilirubin levels. Some children need to be tested several times

"It feels very good to get started with Neo-Bilirubin sales in India, where there is a great need for the product. The market for bilirubin blood tests exceeds 7.5 million tests annually," says Magdalena Tharaldsen, Director International Business Development for Calmark. "I am also very happy to be able to extend the agreement with r2 Diagnostics, which already knows Calmark's POC-system!"

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 09-05-2022 15:51 CET.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93

Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at  




Documents & Links